Alamar Biosciences is a biotechnology company focused on precision proteomics and biomarker discovery for life science research. The company develops the NULISA technology, which enables ultra-high sensitivity and high specificity analysis of hundreds of protein biomarkers in a single sample from as little as 10 microliters of biofluid. This technology is designed to support the earliest detection of disease and is currently available for research use only, not for diagnostic procedures. The company’s team previously created RNAscope, an ultra-sensitive in situ RNA detection technology for spatial genomics, and has applied insights from that platform to maximize signal-to-noise ratios in protein analysis. Alamar Biosciences serves the life science research sector, with applications in areas such as Alzheimer’s disease research, as evidenced by studies using its technology. The company is located in Fremont, California, and participates in major healthcare conferences to share its advancements in proteomics and biomarker analysis.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage investors.alamarbio.com
Sector Healthcare IR page investors.alamarbio.com
Tags
proteomics, biomarker discovery, protein analysis, spatial genomics, rna detection, life science research, alzheimer's research, NULISA, RNAscope
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q2 2026 Q1 2026
Revenue 33.545M 29.427M 26.035M
Net profit -13.342M -13.199M -21.325M
Free cash flow -15.195M -14.964M -20.947M

Figure Q3 2026 Q2 2026 Q1 2026
Share price 34.07 27.09 —
P/FCF -38.95 -31.41 —

Filed figures

Figure Dec 2025
Balance sheet detail
Trade receivables (USD) 12.8M
Lease liabilities (USD) 31.7M
Cash and deposits (USD) 30M
Right-of-use assets (USD) 26.1M
Reported May 8, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended September 30, 2026.

Recent Highlights

•Generated $33.5 million of total revenue for the third quarter of 2026, an increase of 68% as compared to the corresponding period of 2025

•Selected by UK Biobank to profile 80,000 samples for study targeting earlier detection, prevention and treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions

•Launched a strategic scientific collaboration with GSK for large-scale 60,000-sample study to advance precision medicine across respiratory, liver, kidney, neurological and autoimmune conditions

•Announced publication of first longitudinal treatment response for Alzheimer’s disease using NULISA platform published in Lancet Neurology

•Raising full-year 2026 revenue guidance to $121 million to $123 million, representing growth of 64% at the midpoint of the range as compared to 2025

“Our third quarter results reflect continued strong demand for our platform, with revenue up 68%

October 28, 2026

Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentations

Fremont, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced researchers at Emory University have identified a 10-protein blood signature that distinguished patients with amyotrophic lateral sclerosis (ALS) from healthy controls with 98.3% balanced accuracy in an independent validation cohort. The study, published in Nature Communications, used Alamar Biosciences’ NULISA™ technology to measure more than 300 neurological and inflammatory proteins in each blood sample.

ALS can be difficult to diagnose, particularly early in the disease or when symptoms resemble those of other neurological conditions. Researchers are investigating whether blood-based biomarkers could eventually help clinicians identify patients who need specialist evaluation sooner. The newly reported signature remains a research finding, not a clinically validated screening or diagnostic test.

“We saw the proteins we expected, like neurofilament and phosphorylated tau, but we also found differences in proteins that hadn’t been linked to ALS in blood before,” said Eleanor Varian Thomas, MD, assistant professor at Emory University School of Medicine. “The combination of established and new biomarkers into a single protein signature, identified ALS far more accurately than neurofilament alone. Several of these new proteins may also tell us something about ALS biology itself, which we plan to explore as we test the protein signature in larger and more diverse patient groups.”

"ALS patients and their families often wait far too long for answers," said Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences. "We built NULISA to measure low-abundance proteins in blood that other technologies struggle to see, and to measure many of them at once. This study shows why that matters. By profiling brain-derived and inflammatory proteins together, the Emory team identified a multi-protein signature that outperformed single marker testing.

The Emory University Center for Neurodegenerative Diseases and Emory ALS Center researchers initially profiled plasma from 632 ALS patients and 160 healthy controls using NULISAseq™ CNS and Inflammation panels. They developed a 10-protein signature and evaluated it in a separate validation cohort of 144 ALS patients and 37 controls.

In that validation cohort, the 10-protein signature achieved 98.3% balanced accuracy (AUC 0.992), compared with 89.9% (AUC 0.916) for neurofilament light chain (NFL) alone, an established blood biomarker of axonal damage. The model also identified some ALS patients missed by NFL alone, including patients with relatively little disability, a group that can present diagnostic challenges.

The protein signature combines the established neurofilament markers NFL and NEFH with pTau-181 and VEGFA, which have prior links to ALS, and six proteins not previously reported as ALS blood biomarkers: CALCA, NRGN, PTX3, TREM1, FOLR1 and LAMP3. Some of these proteins help the signature identify people who do not have ALS, which is important for distinguishing ALS from other conditions. One protein, FOLR1, was especially useful in correctly classifying people without ALS whose NFL levels were elevated, which reduced false positive results compared with NFL alone. Its performance illustrates the potential value of measuring multiple neurological and inflammatory proteins together rather than relying on one marker.

About Alamar Biosciences

Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.

Forward Looking Statements

This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ ability to help enable the earliest detection of disease. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed with the SEC on August 11, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

  • October 26, 2026

  • Gustav Ceder

Product:
Topic:
Disease Area:
Sample Type:

Back to Publications​

By the time the Singapore Human Proteome Organization (HUPO) congress began, streets were being closed ahead of the Formula One Grand Prix. The humidity was a considerable change from the snow outside last year’s meeting in Toronto.

HUPO assembled 1,428 delegates from 45 countries under the theme “Proteomics Plus: Transforming Lives.” Across the September 27–October 1 program, conversations kept returning to questions that reach beyond the proteomics community: who will develop disease, why treatment fails, and whether a computational model can help us decide which experiment to run next.

The program itself reflected a field broadening its reach. Alongside the main scientific sessions were pre-congress workshops and training courses, short flash talks linked to poster sessions, and mentoring and networking for early-career researchers. The Early Career Researcher (ECR) program also featured manuscript, poster and three-minute thesis competitions. HUPO continued its interactive Bioinformatics Hub format, with 11 sessions spanning AI, multiomics and reproducibility. One, led by the Human Protein Atlas, explored integrating multiomics data and AI tools into its resources.

The exhibition hall and industry-supported seminars added another dimension. Thermo Fisher Scientific and Olink shared a booth for the first time, while Illumina showcased proteomics approaches for population-scale studies. Both hosted scientific seminars. Their presence underscored how technology development, data analysis and clinical research are increasingly part of the same conversation…

Prompts

Alamar Biosciences, Inc. (ticker ALMR), listed in United States.

ETFs Holding Alamar Biosciences, Inc.

ETF Weight in ETF Shares Market value As of
ARKG 2.03% 1,207,894 $ 37.01M Nov 18, 2026
LFSC 0.24% 9,757 $ 297.979K Aug 31, 2026
RESM 0.05% 67 $ 1,815.03 Jun 30, 2026
MSSM 0.01% 2,409 $ 73.571K Aug 31, 2026